The breakthrough in CML treatment was the introduction of Tyrosine Kinase Inhibitors (TKIs), such as the first generation imatinib, targeting the main CML oncogene—constitutively activated BCR-ABL1 kinase. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.